8735428

Celgene sued Dr. Reddy's in an ANDA/Hatch-Waxman action concerning pomalidomide (POMALYST®) patents, including U.S. Pat. Nos. 8,198,262; 8,735,428; 8,828,427; and 9,993,467. The narrative states that US3845770 does not appear to have been asserted in this case, despite its association with the patent-page litigation listing. Final judgment was entered on February 23, 2022.

Hatch-Waxman ANDA litigation. Consent judgment entered June 15, 2022 (Judge Esther Salas): permanent injunction; all claims/counterclaims dismissed with prejudice. Patents-in-suit expressly included 8,828,427 plus '262, '939, '428, '467, '5939.

Hatch-Waxman ANDA litigation filed after Dr. Reddy's ANDA (Mar. 29, 2019) and Paragraph IV notice (May 31, 2019); asserted '262, '3939, '428, '427, and '467. Outcome not confirmed in the sources reviewed.

Celgene filed a § 271 patent infringement action against Synthon in M.D.N.C. asserting US 8,198,262, 8,673,939, 8,735,428, and 8,828,427. The case was terminated July 25, 2018 by a stipulation of dismissal, described as a parallel/companion filing to the New Jersey action.

Celgene filed a 35 U.S.C. §271 action against Par Pharmaceutical and others in D.N.J. involving the '428 patent. The case was terminated on Feb. 6, 2019, consistent with the Pomalyst ANDA settlements, though the disposition was not confirmed in the retrieved sources.

Celgene brought a §271(e)(2) ANDA action against Hetero in D.N.J. regarding the '428 patent. Hetero counterclaimed for declaratory judgment of invalidity/non-infringement of the '428 patent; the court issued a Markman ruling on 'treating multiple myeloma' in the '262, '3,939 and '428 patents, and the case was resolved by settlement.

Later-filed Hetero action in D.N.J. relating to the '428 patent; the narrative states it was resolved/settled.

Additional matter listed in the Google Patents family litigation record for the '428 patent; pomalidomide ANDA/related matter; parties not confirmed.

Consolidated antitrust litigation in D.N.J. in which the '428 patent is cited as part of the challenged Celgene patent portfolio; the court resolved Noerr-Pennington/sham litigation motions in June 2024.

Antitrust action in which the '428 patent is cited as part of the challenged Celgene patent portfolio; Blue Cross LA sued Celgene in S.D.N.Y. Status is generally pending/consolidated.

Antitrust action in which the '428 patent is cited as part of the challenged Celgene patent portfolio; plaintiff sued Celgene in S.D.N.Y. Status is generally pending/consolidated.

Antitrust action in which the '428 patent is cited as part of the challenged Celgene patent portfolio; CenterWell Pharmacy sued Celgene in S.D.N.Y. Status is generally pending/consolidated.

Antitrust action in which the '428 patent is cited as part of the challenged Celgene patent portfolio; MSP Recovery Claims sued Celgene in D.N.J. Status is generally pending/consolidated.

Antitrust action in which the '428 patent is cited as part of the challenged Celgene patent portfolio; Molina Healthcare sued Celgene in D.N.J. Status is generally pending/consolidated.

Antitrust action in which the '428 patent is cited as part of the challenged Celgene patent portfolio; The Cigna Group sued Celgene in D.N.J. Status is generally pending/consolidated.

Hatch-Waxman ANDA patent-infringement suit involving pomalidomide (ANDA No. 213234). Patents asserted included U.S. 8,198,262, 8,673,939, 8,735,428, 8,828,427, and U.S. 9,993,467. A consent judgment enjoined Dr. Reddy's from infringing the patents-in-suit until expiration and dismissed all claims, counterclaims, and defenses with prejudice.